Ostrem Bridget E L, Odell Elizabeth, Grelli Kimberly N, Kramer Katelin, Chan Natalie, Jiang Fei, Xu Duan, Barkovich A James, Barkovich Matthew J, Ferriero Donna M, Gano Dawn
Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco, San Francisco, CA, USA.
Divison of Neonatology, UCSF Benioff Children's Hospital Oakland, Oakland, CA, USA.
Pediatr Res. 2025 Sep 20. doi: 10.1038/s41390-025-04387-1.
Preterm infants who receive caffeine for apnea of prematurity have improved neurodevelopmental outcomes compared to untreated infants. The optimal dosing regimen for neuroprotection is unknown. We hypothesized that higher caffeine exposure is associated with improved neurodevelopmental performance.
We quantified caffeine exposure in a previously reported cohort of 106 infants born at ≤32 gestational weeks who received brain MRIs during the neonatal hospitalization. Infants were subdivided into tertiles based on average daily caffeine exposure (ADCE). Bayley-III examinations were performed on 69 participants at 30 months corrected age. Neurodevelopmental impairment (NDI) was defined as a score of ≤85 on the Bayley-III motor, language, and/or cognitive subscales. We evaluated the relationship between caffeine exposure, neuroimaging abnormalities, and neurodevelopmental performance.
Higher ADCE was associated with decreased odds of NDI (OR 0.69, 95% C.I. 0.50-0.95) but not with MRI abnormalities. High dose caffeine was associated with improved motor (mean difference 10.9, 95% C.I. 0.7-21.0), language (mean difference 15.2, 95% C.I. 3.4-27.0), and cognitive (mean difference 13.0, 95% C.I. 0.6-25.4) performance compared to low dose in multivariable analyses adjusted for gestational age and respiratory disease.
Higher sustained caffeine exposure during the neonatal hospitalization is associated with improved neurodevelopmental outcomes in preterm infants.
Premature infants who receive caffeine for apnea of prematurity have improved neurodevelopmental outcomes compared to untreated infants. The optimal dosing strategy for neuroprotection is unknown. We found that higher average daily exposure during the neonatal hospitalization was associated with reduced neurodevelopmental impairment at 30 months corrected age. High dose caffeine was associated with improved motor, language, and cognitive performance on the Bayley-III compared to low dose caffeine in multivariable analyses adjusted for gestational age and respiratory disease. Preterm infants may benefit from higher maintenance doses and/or from continuing caffeine beyond the period of respiratory need.
与未接受治疗的早产儿相比,接受咖啡因治疗早产儿呼吸暂停的患儿神经发育结局有所改善。神经保护的最佳给药方案尚不清楚。我们假设较高的咖啡因暴露量与改善的神经发育表现相关。
我们对先前报道的106例孕龄≤32周、在新生儿住院期间接受脑部MRI检查的婴儿队列中的咖啡因暴露量进行了量化。根据平均每日咖啡因暴露量(ADCE)将婴儿分为三分位数。在69名矫正年龄为30个月的参与者中进行了贝利婴幼儿发展量表第三版(Bayley-III)检查。神经发育障碍(NDI)定义为贝利婴幼儿发展量表第三版运动、语言和/或认知分量表得分≤85分。我们评估了咖啡因暴露、神经影像学异常与神经发育表现之间的关系。
较高的ADCE与较低的NDI几率相关(比值比0.69,95%置信区间0.50 - 0.95),但与MRI异常无关。在根据孕龄和呼吸系统疾病进行调整的多变量分析中,与低剂量咖啡因相比,高剂量咖啡因与运动(平均差异10.9,95%置信区间0.7 - 21.0)、语言(平均差异15.2,95%置信区间3.4 - 27.0)和认知(平均差异13.0,95%置信区间0.6 - 25.4)表现改善相关。
新生儿住院期间较高的持续咖啡因暴露量与早产儿改善的神经发育结局相关。
与未接受治疗的早产儿相比,接受咖啡因治疗早产儿呼吸暂停的患儿神经发育结局有所改善。神经保护的最佳给药策略尚不清楚。我们发现,新生儿住院期间较高的平均每日暴露量与矫正年龄30个月时神经发育障碍的减少相关。在根据孕龄和呼吸系统疾病进行调整的多变量分析中,与低剂量咖啡因相比,高剂量咖啡因与贝利婴幼儿发展量表第三版上改善的运动、语言和认知表现相关。早产儿可能从更高的维持剂量和/或在呼吸需求期之后继续使用咖啡因中获益。